Research programme: cancer therapeutics - GlobalAcorn
Latest Information Update: 05 Sep 2023
Price :
$50 *
At a glance
- Originator GlobalAcorn
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route) prior to March 2023 (GlobalAcorn website, March 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in United Kingdom
- 07 Jul 2016 Preclinical trials in Cancer in United Kingdom (unspecified route)